Asymptomatic screening for SARS CoV-2 prior to commencement of biologic therapies in patients with inflammatory bowel disease - a potentially harmful practice

Dig Liver Dis. 2020 Nov;52(11):1250-1251. doi: 10.1016/j.dld.2020.08.035. Epub 2020 Aug 27.

Authors

Ralley E Prentice¹, Aysha H Al-Ani¹, Katherine Bond², Doug Johnson², Britt Christensen³

Affiliations

¹ Department of Gastroenterology, The Royal Melbourne Hospital, Melbourne, Vic., Australia.
² Department of Infectious Diseases, The Royal Melbourne Hospital, Melbourne, Vic., Australia.
³ Department of Gastroenterology, The Royal Melbourne Hospital, Melbourne, Vic., Australia. Electronic address: britt.christensen@mh.org.au.

No abstract available

Publication types

Letter
Comment

MeSH terms

Betacoronavirus
Biological Therapy / adverse effects
COVID-19
Coronavirus Infections*
Humans
Immunization
Inflammatory Bowel Diseases* / diagnosis
Inflammatory Bowel Diseases* / drug therapy
Pandemics*
Pneumonia, Viral*
SARS-CoV-2
Severe acute respiratory syndrome-related coronavirus*